Sona Nanotech, Inc (TSE:SONA) has released an update.
Sona Nanotech Inc. has filed a provisional patent for a new photothermal light medical device designed to work with their gold nanorods for efficient cancer treatment. The device is undergoing a pre-clinical study at Dalhousie University and has garnered positive feedback from both the FDA and a panel of leading U.S. surgeons. Additionally, the company has strengthened its Advisory Board with the appointment of Dr. Carman Giacomantonio, a surgical oncologist involved in the current study.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.
